quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 29, 2026

Qualcomm Is Down 37% From Its High and Reports Wednesday. Is the Stock a Buy?

View original at nasdaq.com
Qualcomm Is Down 37% From Its High and Reports Wednesday. Is the Stock a Buy? Key Points Qualcomm reports fiscal third-quarter results after the market closes on Wednesday, July 29…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The consensus analyst rating on Qualcomm is hold, with an average price target of $221.23, about 36% above the current price of $162.88.

    60% confidence

  • Qualcomm delivered results in line with guidance, reflecting solid execution navigating a challenging memory environment.

    60% confidence

  • The author would rather wait for more information before buying Qualcomm stock, even at the risk of missing a rebound.

    60% confidence

  • A custom silicon engagement with a leading hyperscaler remains on track for initial shipments later this calendar year.

    60% confidence

  • Qualcomm expects handset revenue from Chinese customers to bottom in the fiscal Q3 quarter and return to sequential growth in the following quarter.

    60% confidence

Data points we hold from this source

Qualcomm Incorporated · stock price162.88 USD
Qualcomm Incorporated · market share221.23 USD
Qualcomm Incorporated · cash3.7 USD
Qualcomm Incorporated · margin72 percent
Qualcomm Incorporated · eps2.65 USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Qualcomm Is Down 37% From Its High and Reports Wednesday. Is the Stock a Buy? — Source | Via News | pt.VIA.NEWS